BENNETT LEVINE, M.D.; AUSTIN S. WEISBERGER, M.D.
The beneficial effects of nitrogen mustard (HN2) in some cases of bronchogenic carcinoma is well known.1-15 The number of patients receiving benefit from HN2 therapy has varied from 18% to 74%.1-3, 5-11 Most observers have made no correlation between the cell type of carcinoma and the degree of response to HN2 therapy. Several investigators, however, have found that the undifferentiated or anaplastic type of bronchogenic carcinoma has responded best to HN2 therapy.2, 5, 7, 8, 11, 15 In the present study an attempt was made to correlate the response to HN2 therapy with the type of bronchogenic carcinoma present. In
LEVINE B, WEISBERGER AS. THE RESPONSE OF VARIOUS TYPES OF BRONCHOGENIC CARCINOMA TO NITROGEN MUSTARD(THE RESPONSE OF VARIOUS TYPES OF BRONCHOGENIC CARCINOMA TO NITROGEN MUSTARD*†)(THE RESPONSE OF VARIOUS TYPES OF BRONCHOGENIC CARCINOMA TO NITROGEN MUSTARD*†). Ann Intern Med. 1955;42:1089–1096. doi: 10.7326/0003-4819-42-5-1089
Download citation file:
Published: Ann Intern Med. 1955;42(5):1089-1096.
Hematology/Oncology, Lung Cancer, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use